Form 8-K - Current report:
SEC Accession No. 0001193125-24-164550
Filing Date
2024-06-20
Accepted
2024-06-20 17:01:31
Documents
14
Period of Report
2024-06-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d841500d8k.htm   iXBRL 8-K 45001
2 EX-10.1 d841500dex101.htm EX-10.1 4384
  Complete submission text file 0001193125-24-164550.txt   175886

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20240618.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20240618_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20240618_pre.xml EX-101.PRE 11264
17 EXTRACTED XBRL INSTANCE DOCUMENT d841500d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 241057311
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)